Bio-Rad Laboratories Overview
Bio-Rad Laboratories (BIO.B) has a ROE of 3.1%, below the Healthcare sector average of 22.76%.
Get informed when a big investor buys or sells
+ Follow3.10%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Bio-Rad Laboratories (BIO.B) currently reports a ROE of 3.1%. That is below the Healthcare sector average of 22.76%. Use the charts on this page to explore Bio-Rad Laboratories's ROE history and peer comparisons.
Bio-Rad Laboratories's ROE of 3.1% is lower than the Healthcare sector average of 22.76%. That is roughly 86.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Bio-Rad Laboratories's current 3.1% should be judged against Healthcare norms (sector average: 22.76%) and against BIO.B's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of 3.1%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 22.76%. From there, open related valuation or income-statement pages for Bio-Rad Laboratories, and consider following BIO.B for alerts when major investors trade the stock.
Bio-Rad Laboratories is classified in the Healthcare sector. On ROE, it currently shows 3.1% versus a sector average near 22.76%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BIO.B with unrelated industries.
